Effect of modified brain histamine contents on prolactin and thyrotropin secretion in male rats.
Effects of modified brain histamine contents on thyrotropin and prolactin secretion were studied in male rats. Under basal conditions the histamine content in the hypothalamus was approximately 8-10-fold higher than that in the striatum and the rest of the brain. L-histidine (1000 mg/kg, ip), a histamine precursor, and metoprine (20 mg/kg, ip), an inhibitor of histamine methyltransferase, elevated histamine content in the brain by 65% and 167%, respectively. When the treatments were given together an additive effect (119-250% increase) on brain histamine was observed. Metoprine significantly decreased serum prolactin levels, while L-histidine had no effect. This effect of metoprine was not modified by treatment with L-histidine. Thus, metoprine has an inhibitory effect on prolactin secretion that is not related to elevated brain histamine contents. The increased brain histamine content after L-histidine treatment had no effect on prolactin secretion. Basal levels of serum thyrotropin were decreased by both L-histidine and metoprine, L-histidine being more potent. In rats treated with alpha-fluoromethylhistidine, an inhibitor of L-histidine decarboxylase, the cold-induced (rats kept for 60 min at +4 degrees C) thyrotropin secretion was increased while the stress-induced prolactin secretion was decreased. In these rats, metoprine did not affect thyrotropin release but blunted the prolactin response. In conclusion, endogenous histamine inhibits thyrotropin secretion but does not affect prolactin release. Owing to its other effects, metoprine is not suitable as a tool to elevate endogenous histamine contents in the brain, at least when the regulation of anterior pituitary hormone release is being studied.
Tuominen
R K
RK
Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Helsinki, Finland.
Tuomisto
L
L
Männistö
P T
PT
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003080:Cold Temperature; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006632:Histamine / Q000378:metabolism*; D006637:Histamine N-Methyltransferase / Q000037:antagonists & inhibitors; D006639:Histidine / Q000494:pharmacology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008762:Methylhistidines / Q000494:pharmacology; D011388:Prolactin / Q000378:metabolism*; D011739:Pyrimethamine / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013312:Stress, Physiological / Q000503:physiopathology; D013972:Thyrotropin / Q000378:metabolism*
D004791:Enzyme Inhibitors; D008762:Methylhistidines; C006308:metoprine; D006639:Histidine; C028309:alpha-fluoromethylhistidine; D006632:Histamine; D011388:Prolactin; D013972:Thyrotropin; D006637:Histamine N-Methyltransferase; D011739:Pyrimethamine